ADRB2 Gene
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#4477AA; color:white;">ADRB2</th></tr>
<tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>
</table>
</div>
Overview
ADRB2 encodes the β2-adrenergic receptor (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].
...
ADRB2 Gene
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#4477AA; color:white;">ADRB2</th></tr>
<tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>
</table>
</div>
Overview
ADRB2 encodes the β2-adrenergic receptor (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].
The β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].
Molecular Biology and Structure
Gene Organization
The ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:
- TATA box: Core promoter element
- CRE elements: cAMP response elements for regulated expression
- AP-1 sites: Responsive to growth factors and cytokines
- GRE: Glucocorticoid response elements
- NF-κB elements: Allows inflammatory regulation
Multiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].
Protein Structure
The β2-adrenergic receptor has classical GPCR architecture:
- N-terminal extracellular domain (1-39 aa): Contains two N-linked glycosylation sites
- Transmembrane domains (TM1-TM7): Seven α-helices forming the ligand-binding pocket
- Extracellular loops (ECL1-ECL3): ECL2 contains a conserved disulfide bond
- Intracellular loops (ICL1-ICL3): ICL3 is the primary G protein coupling domain
- C-terminal tail (342-413 aa): Contains serine/threonine phosphorylation sites
The ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:
- Asp113 in TM3 (counterion for catecholamine amine)
- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)
- Phe282 (hydrophobic interactions with aromatic ring)
Splice Variants
Multiple splice variants of ADRB2 have been described:
- β2-AR1: Full-length 413 aa (predominant)
- β2-AR2: Alternative C-terminus
- Truncated variants: May have distinct signaling properties
Signaling Pathways
Primary Gs-cAMP Pathway
Upon agonist binding:
Conformational change activates Gs protein
Gαs-GTP stimulates adenylyl cyclase
cAMP production increases
PKA activation leads to substrate phosphorylation
Physiological effects on muscle relaxation, glycogenolysis, gene transcriptionAlternative Gi/o Coupling
In some cell types, β2-AR couples to Gi/o:
- Inhibition of adenylyl cyclase reduces cAMP
- βγ subunits activate PI3K pathways
- Cell-type specificity determines coupling preference
β-Arrestin Pathways
β2-AR signals through β-arrestins independently of G proteins:
- ERK1/2 activation via β-arrestin scaffolds
- Akt activation through similar mechanisms
- Receptor internalization and recycling
- Biased signaling potential for drug design
Receptor Dynamics
β2-AR exhibits unique properties:
- Constitutive activity: Some basal signaling without agonist
- Inverse agonism: Some ligands reduce baseline activity
- Allosteric modulators: Bind at distinct sites
- Oligomerization: May form heteromers with other GPCRs
Role in Neurodegenerative Diseases
Alzheimer's Disease
Memory Consolidation
β2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:
- Hippocampal LTP: β2-AR activation enhances long-term potentiation
- Memory enhancement: Agonists improve consolidation in multiple paradigms
- cAMP/PKA/CREB pathway: Required for consolidation effects
- Time window: Effects greatest during post-training period
The noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.
Amyloid Pathology
β2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:
- APP processing: cAMP can influence α-secretase activity
- Aβ production: Effects are context-dependent
- Synaptic protection: β2-AR activation protects against Aβ-induced synaptic dysfunction
- Neuronal survival: Anti-apoptotic signaling through PI3K/Akt
Neuroinflammation
β2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:
- Microglial inhibition: β2-AR activation reduces pro-inflammatory cytokine release
- TNF-α suppression: Reduces microglial activation
- IL-1β and IL-6: Suppressed by β2-agonists
- Therapeutic potential: Reduces neuroinflammation in AD models
Genetic Associations
Several studies link ADRB2 variants to AD risk[@mittal2017]:
- Functional polymorphisms may alter receptor signaling
- Population-specific effects observed in different cohorts
- Gene-environment interactions with lifestyle factors
Parkinson's Disease
Neuroprotection
β2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:
- Dopaminergic neuron survival: Protects against MPTP and 6-OHDA toxicity
- α-Synuclein effects: May reduce aggregation or toxicity
- Anti-apoptotic signaling: Through cAMP/PKA and PI3K pathways
- Anti-inflammatory: Microglial suppression
Clinical Trials
β2-agonists are being investigated for PD:
- Formoterol: Long-acting β2-agonist in clinical trials
- Safety profile: Generally well-tolerated
- CNS penetration: A challenge for some compounds
Autonomic Function
β2-AR contributes to autonomic regulation:
- Cardiac effects: Modulates heart rate and contractility
- Blood pressure: Influences vascular tone
- PD autonomic dysfunction: Relevant to non-motor symptoms
Stroke and Cerebral Ischemia
β2-AR activation provides neuroprotection in stroke models[@park2020]:
- Infarct reduction: Reduces cerebral infarction
- Anti-apoptotic: Promotes neuronal survival
- Anti-inflammatory: Reduces post-ischemic inflammation
- Angiogenesis: May promote recovery
Mood Disorders
The β2-adrenergic system is relevant to depression:
- β2-AR downregulation: Seen in depression
- Antidepressant effects: Some antidepressants affect β2-AR signaling
- Therapeutic targeting: β2-agonists have been explored
Expression Pattern
Central Nervous System
In the brain, β2-AR is expressed in:
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Cerebral cortex: Pyramidal neurons in all layers
- Cerebellum: Purkinje cells and granule cells
- Amygdala: Principal neurons
- Hypothalamus: Regulatory neurons
- Basal forebrain: Cholinergic projection neurons
Peripheral Tissues
Highest peripheral expression:
- Lungs: Bronchial smooth muscle (primary site)
- Heart: Cardiac myocytes
- Liver: Hepatocytes
- Skeletal muscle: Muscle fibers
- Adipose tissue: Brown and white adipocytes
Subcellular Localization
- Plasma membrane: Primary location
- Endosomal compartments: Internalized receptors
- Nucleus: Some nuclear localization reported
Therapeutic Implications
Respiratory Diseases
β2-AR agonists are first-line treatments:
| Drug | Type | Half-life | Clinical Use |
|------|------|-----------|--------------|
| Albuterol | SABA | 4-6 hours | Acute asthma |
| Salmeterol | LABA | 12 hours | Maintenance asthma |
| Formoterol | LABA | 12 hours | Asthma, COPD |
| Indacaterol | LABA | 24 hours | COPD maintenance |
Neurodegeneration
Therapeutic strategies include:
Brain-penetrant agonists: Formoterol, arformoterol
β-arrestin biased ligands: G protein-independent effects
Allosteric modulators: Increase agonist potency
Combination approaches: With cholinesterase inhibitorsCardiovascular
β2-AR agonists have limited cardiac use:
- Acute decompensation: Rarely used due to β1 effects
- Peripheral vasodilation: Some β2-agonists cause hypotension
- Safety concerns: Tremor and tachycardia
Animal Models
Genetic Models
- Adrb2 knockout mice: Viable with respiratory and metabolic phenotypes
- Transgenic overexpression: Tissue-specific models
- Humanized mice: For drug testing
Phenotypes
- Respiratory: Altered bronchial responsiveness
- Metabolic: Changes in glycogen metabolism
- Cardiac: Mild cardiac phenotypes
- Behavioral: Altered stress responses
Disease Models
Tested in:
- MPTP-induced parkinsonism
- 6-OHDA lesion models
- Transgenic AD models
- Cerebral ischemia models
Pathway Diagram
Mermaid diagram (expand to render)
Key Publications
[Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation](https://pubmed.ncbi.nlm.nih.gov/24790844/)[@lefkowitz2014]
[Moreau et al., 2018 - Formoterol rescues memory in AD models](https://pubmed.ncbi.nlm.nih.gov/29686311/)[@formoterol2018]
[Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/30626698/)[@birmingham2019]
[Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors](https://pubmed.ncbi.nlm.nih.gov/17291618/)[@galandrin2007]
[Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization](https://pubmed.ncbi.nlm.nih.gov/27029639/)[@nichols2016]
[Ibayashi et al., 2019 - Beta2-AR signaling in glial cells](https://pubmed.ncbi.nlm.nih.gov/31297657/)[@ibayashi2019]
[Mittal et al., 2017 - ADRB2 polymorphisms and AD risk](https://pubmed.ncbi.nlm.nih.gov/28145406/)[@mittal2017]
[Yan et al., 2019 - Beta2-agonists for PD disease modification](https://pubmed.ncbi.nlm.nih.gov/31154832/)[@yan2019]
[Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/29488493/)[@wang2018]
[Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production](https://pubmed.ncbi.nlm.nih.gov/28222568/)[@chen2017]
[Yang et al., 2016 - Beta2-AR and neuroinflammation in AD](https://pubmed.ncbi.nlm.nih.gov/27117268/)[@yang2016]
[Liu et al., 2018 - Beta2-AR in PD models](https://pubmed.ncbi.nlm.nih.gov/29604376/)[@liu2018]
[Xiao et al., 2019 - Beta-adrenergic signaling in the heart](https://pubmed.ncbi.nlm.nih.gov/31788967/)[@xiao2019]
[Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection](https://pubmed.ncbi.nlm.nih.gov/32877911/)[@park2020]See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)
- [Beta-Adrenergic Receptors](/entities/beta-adrenergic-receptors)
- [Memory Consolidation](/mechanisms/memory-consolidation)
- [Neuroprotection](/therapeutics/neuroprotection)
- [Norepinephrine](/entities/norepinephrine)
- [Formoterol](/therapeutics/formoterol)
- [Hippocampus](/brain-regions/hippocampus)
External Links
- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)
- [UniProt: ADRB2](https://www.uniprot.org/uniprotkb/P07550)
- [Ensembl: ADRB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252)
- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)
- [OMIM: ADRB2](https://omim.org/entry/109630)
- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)
Pathway Diagram
The following diagram shows the key molecular relationships involving ADRB2 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)